Home/ Stocks/ GRI

GRI Bio, Inc. Common Stock

GRI XNAS

$1.47 -0.09 (-5.81%) ▼ 15-min delayed

Open

$1.55

High

$1.55

Low

$1.41

Volume

32.7K

Market Cap

$2.74M

About GRI Bio, Inc. Common Stock

GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 5 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$0	$-1,998,000	$-1.61
FY 2025	$0	$-11,956,000	$-121.80
Q3 2025	$0	$-3,359,000	$-1.28
Q2 2025	$0	$-2,892,000	$-1.31

Related Market News

No specific coverage for GRI yet. Check out our latest market news or earnings calendar.

Get GRI Alerts

Stay ahead with breaking news, price alerts, and expert analysis on GRI Bio, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.